BCG Vaccine News and Research

RSS

The BCG Vaccine is a vaccine containing bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, with non-specific immunoadjuvant and immunotherapeutic activities. Although the mechanism of its anti-tumor activity is unclear, immunization with BCG vaccine likely activates a Th1 cytokine response that includes the induction of interferon. Vaccination with BCG vaccine may be immunoprotective against infection with Mycobacterium tuberculosis.

BCG vaccine protects against infection in adulthood when most transmission occurs, study shows

Previously thought to be effective for 10-15 years, a new case-control study found that if given in early teenage years (12-13), the Bacillus Calmette-Guérin (BCG) vaccine protected over 50% of UK children against TB for at least 20 years, then waned.

1 Sep 2017

Clinical study shows new mechanism that BCG vaccine uses to reverse advanced type 1 diabetes

Interim results from a FDA-approved clinical trial testing the generic vaccine bacillus Calmette-Guérin (BCG) to reverse advanced type 1 diabetes are being presented at the 75th Scientific Sessions of the American Diabetes Association.

12 Jun 2017

One-shot vaccine passes key preclinical test in newborn monkey models

Newborns are highly vulnerable to infections and don't respond optimally to most vaccines because their young immune systems typically mount weak antibody responses.

24 Mar 2017

Insights into immune system pathways may be key to developing effective TB vaccine

New research findings provide insight into the immune system pathways that may be key to developing an effective tuberculosis (TB) vaccine.

22 Dec 2016

Antibody protection may help control infection caused by TB bacteria

A study led by investigators from the Ragon Institute of MGH, MIT and Harvard finds evidence that antibody protection may help control infection with the bacteria that causes tuberculosis (TB).

4 Oct 2016

New skin test for TB infection proves safe, effective in clinical trials

A new skin test for tuberculosis infection has proven safe, easy to administer and accurate in two Phase III clinical trials, according to research presented at the ATS 2016 International Conference.

19 May 2016

New biomarker discovery could improve chances of developing effective TB vaccine

A team of scientists led by Oxford University have made a discovery that could improve our chances of developing an effective vaccine against Tuberculosis.

12 Apr 2016

Analyzing potential TB vaccine

When results from a landmark tuberculosis vaccine trial in Cape Town, South Africa were published in The Lancet in February 2013, the headlines were grim, despite hopes that the trial would point toward a successful way to thwart one of the globe's biggest public health threats.

13 Nov 2015

GHIT Fund invests $10.7 million to fight malaria, TB, leishmaniasis and dengue

The Global Health Innovative Technology Fund, which in the last two years has invested US$43 million to develop innovative tools for fighting diseases worldwide, today announced it is investing $10.7 million at multiple points in the product development pipeline to seek new interventions for malaria, tuberculosis (TB), leishmaniasis and dengue.

5 Nov 2015

Liposomal sizing and the Coulter principle: an interview with Professor Melvin E. Klegerman

For about the last 25 years, the cardiology group here have been developing a platform technology for both the diagnosis and treatment of atherosclerosis.

From Beckman Coulter Life Sciences - Particle Counting and Characterization 28 Oct 2015

Generex agrees to acquire 51% equity interest in Hema Diagnostic Systems

Generex Biotechnology Corporation today announced that it has entered into a non-binding Letter of Intent (LOI) with Hema Diagnostic Systems, LLC (HDS), a Florida company that designs and manufactures proprietary infectious disease detection technologies.

30 Sep 2015

Radboud university medical center reveals how BCG vaccine works against tuberculosis

Not only the acquired immune system but also the innate immune system has a memory. And the BCG vaccine against tuberculosis can stimulate this memory. After a BCG vaccination the innate immune system responds better to a wide range of other infections. Mihai Netea and colleagues from Radboud university medical center discovered and described how that works. They think that the old vaccine could be useful for specific target groups, such as the elderly.

23 Sep 2015

New systematic review questions effectiveness of MVA85A vaccine on TB

A new systematic review of animal studies testing a vaccine for tuberculosis raises questions about whether the studies provided sufficient evidence to move into trials of children.

10 Sep 2015

SLU researchers work to prevent several serious infectious diseases

Saint Louis University researchers are attacking influenza on multiple fronts as they search for a universal vaccine that protects people from the flu virus that often mutates year to year with deadly consequences.

9 Sep 2014

Research finds stronger weapon against leprosy and tuberculosis

In many parts of the world, leprosy and tuberculosis live side-by-side. Worldwide there are approximately 233,000 new cases of leprosy per year, with nearly all of them occurring where tuberculosis is endemic.

20 Aug 2014

Tuberculosis in children: an interview with Dr Peter Dodd, University of Sheffield

It was recently announced that new estimates indicated over 650,000 children develop tuberculosis (TB) every year in the 22 countries with a high burden of the disease (HBCs). Which countries are these and why are so many children developing TB in these areas?

29 Jul 2014

Clear advances in the fight against tuberculosis are within reach, say immunologists

Leading immunologists expect to see some clear advances in the fight against tuberculosis, an infectious disease that is widespread the world over. Professor Stefan Kaufmann, Director at the Max Planck Institute for Infection Biology in Berlin, echoed these sentiments at today's launch of the scientific programme for the 64th Lindau Nobel Laureate Meeting at Lindau, Germany.

2 Jul 2014

New TB blood test could eliminate unnecessary treatment

A new screening process for tuberculosis (TB) infections in Canadian prisons could mean that more than 50 per cent of those screened won't undergo unnecessary treatment due to false positives.

6 Jun 2014

ILiAD, Inserm and IPL sign worldwide license agreement for Bordetella pertussis vaccine technology

ILiAD Biotechnologies, LLC, the French National Institute of Health and Medical Research subsidiary, Inserm Transfert SA, and Institut Pasteur de Lille today announced the signing of scientific collaboration and worldwide license agreements for live attenuated Bordetella pertussis vaccine technology, including BPZE1, developed by the laboratory of Professor Camille Locht. This license agreement covers patent rights from Institut Pasteur de Lille, Inserm, National University of Singapore and National University of Ireland Maynooth.

9 Jan 2014

BCG vaccine highly protective against pulmonary TB: Study

The BCG vaccine has been found to be more effective against the most common form of tuberculosis than previously thought, according to a new study in Clinical Infectious Diseases.

20 Dec 2013